Last reviewed · How we verify
Moxonidin
At a glance
| Generic name | Moxonidin |
|---|---|
| Also known as | Moxonidin "Alpharma" |
| Sponsor | University of Aarhus |
| Target | 5-hydroxytryptamine receptor 1A, Alpha-2A adrenergic receptor, Alpha-2C adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | discontinued |
Approved indications
- Essential hypertension
Common side effects
Key clinical trials
- Sympathetic Nervous System Inhibition for the Treatment of Diabetic Nephropathy (Phase 4)
- Open-Label Non-Comparative Study of the Effects of a Combination Antihypertensive Treatment With Moxonidine + Perindopril in Hypertensive Patients With Metabolic Syndrome (Phase 4)
- A Randomized, Placebo-controlled, Double Blind, 4-period, Cross-over Trial, to Study the Effects of Aliskiren, Hydrochlorothiazide and Moxonidine on Endothelial Dysfunction in Obesity Related Hyperten (Phase 4)
- Polycystic Ovary Syndrome - Targeting the Sympathetic Nervous System to Improve Outcomes (Phase 4)
- The Effects of Small Doses of Moxonidine in Patients Undergoing Vascular Surgery (Phase 3)
- Role of Sympathetic Activation in Ischemia Reperfusion Injury (Phase 4)
- Sympathetic Mechanisms in the Cardiovascular and Metabolic Alterations of Obesity (Phase 1)
- A Randomised Trial Examining the Effectiveness of Sympathetic Nervous Inhibition in Alleviating the Metabolic Side Effects of Antipsychotic Medications in Patients With Schizophrenia (Phase 4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |